Belite Bio (NASDAQ:BLTE) Insider Sells $82,660.00 in Stock

Key Points

• Insider sale: Hendrik Scholl sold 500 Belite Bio shares for $82,660, reducing his ownership by 3.33% to 14,500 shares valued at approximately $2.4 million.
• Stock performance: BLTE recently traded down 0.2% to $159.18, with a market capitalization of $6.41 billion and a 52-week range of $75.95 to $200.
• Analyst outlook: Analysts maintain a “Moderate Buy” consensus, with eight Buy ratings, two Holds, one Sell, and an average price target of $218.73. Belite Bio reported a quarterly loss of $0.54 per share, while full-year EPS is projected at -$3.08.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) insider Hendrik Scholl sold 500 shares of Belite Bio stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $165.32, for a total transaction of $82,660.00. Following the completion of the sale, the insider owned 14,500 shares in the company, valued at approximately $2,397,140. This represents a 3.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Belite Bio Trading Down 0.2%

BLTE traded down $0.38 during trading hours on Monday, hitting $159.18. The company's stock had a trading volume of 133,264 shares, compared to its average volume of 175,497. Belite Bio, Inc. Sponsored ADR has a fifty-two week low of $75.95 and a fifty-two week high of $200.00. The company has a 50-day simple moving average of $166.50 and a 200 day simple moving average of $157.74. The firm has a market capitalization of $6.41 billion, a PE ratio of -58.31 and a beta of -1.23.

Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its earnings results on Tuesday, June 30th. The company reported ($0.54) earnings per share (EPS) for the quarter. Research analysts expect that Belite Bio, Inc. Sponsored ADR will post -3.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on BLTE shares. UBS Group reiterated a "buy" rating on shares of Belite Bio in a research report on Thursday, September 3rd. Weiss Ratings restated a "sell (d-)" rating on shares of Belite Bio in a report on Friday. Cantor Fitzgerald lifted their target price on shares of Belite Bio from $266.00 to $270.00 and gave the stock an "overweight" rating in a report on Wednesday, August 12th. HC Wainwright set a $245.00 target price on shares of Belite Bio in a research report on Tuesday, September 8th. Finally, Zacks Research cut shares of Belite Bio from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 18th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Belite Bio has an average rating of "Moderate Buy" and an average price target of $218.73.

Hedge Funds Weigh In On Belite Bio

Several large investors have recently bought and sold shares of the stock. Engineers Gate Manager LP increased its holdings in shares of Belite Bio by 11.4% during the 2nd quarter. Engineers Gate Manager LP now owns 2,773 shares of the company's stock worth $427,000 after purchasing an additional 284 shares during the period. Bank of America Corp DE grew its position in Belite Bio by 104.0% during the first quarter. Bank of America Corp DE now owns 3,778 shares of the company's stock worth $602,000 after buying an additional 1,926 shares in the last quarter. Amundi bought a new position in Belite Bio during the first quarter valued at about $671,000. Royal Bank of Canada increased its stake in Belite Bio by 7.9% during the first quarter. Royal Bank of Canada now owns 2,257 shares of the company's stock valued at $360,000 after acquiring an additional 165 shares during the period. Finally, The Manufacturers Life Insurance Company acquired a new position in Belite Bio in the 1st quarter valued at approximately $3,125,000. 0.53% of the stock is currently owned by institutional investors and hedge funds.

Belite Bio Company Profile

Belite Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for retinal diseases that can lead to vision loss. The company's research centers on addressing biological processes associated with the accumulation of toxic vitamin A byproducts in the eye.

Belite Bio's lead product candidate is tinlarebant, also known as LBS-008, an orally administered retinol-binding protein 4 antagonist. The company is evaluating tinlarebant for Stargardt disease, an inherited retinal disorder, and geographic atrophy associated with dry age-related macular degeneration.

Founded in 2018 and headquartered in San Diego, California, Belite Bio conducts clinical development activities for its retinal disease programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.